Last reviewed · How we verify
Doxycycline and tauroursodeoxycholic acid
Doxycycline and tauroursodeoxycholic acid combination works by reducing inflammation and oxidative stress while promoting bile acid signaling to protect mitochondrial function and reduce hepatocellular injury.
Doxycycline and tauroursodeoxycholic acid combination works by reducing inflammation and oxidative stress while promoting bile acid signaling to protect mitochondrial function and reduce hepatocellular injury. Used for Primary biliary cholangitis (PBC), Non-alcoholic fatty liver disease (NAFLD) / Non-alcoholic steatohepatitis (NASH).
At a glance
| Generic name | Doxycycline and tauroursodeoxycholic acid |
|---|---|
| Also known as | Standard of care therpay |
| Sponsor | Fondazione IRCCS Policlinico San Matteo di Pavia |
| Drug class | Combination therapy (antibiotic + bile acid derivative) |
| Target | Matrix metalloproteinases, FXR (farnesoid X receptor), TGR5 (G-protein coupled bile acid receptor 1) |
| Modality | Small molecule |
| Therapeutic area | Hepatology / Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
Doxycycline is a tetracycline antibiotic with anti-inflammatory and anti-fibrotic properties that inhibit matrix metalloproteinases and reduce inflammatory cytokine production. Tauroursodeoxycholic acid (TUDCA) is a bile acid that activates farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (TGR5), enhancing mitochondrial function and reducing endoplasmic reticulum stress. Together, they target multiple pathways involved in liver disease progression.
Approved indications
- Primary biliary cholangitis (PBC)
- Non-alcoholic fatty liver disease (NAFLD) / Non-alcoholic steatohepatitis (NASH)
Common side effects
- Gastrointestinal disturbance (nausea, diarrhea)
- Photosensitivity (doxycycline-related)
- Abdominal discomfort
Key clinical trials
- Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis
- A Study of Doxycycline and Tauroursodeoxycholic Acid (Doxy/TUDCA) Plus Standard Supportive Therapy Versus Standard Supportive Therapy Alone in Cardiac Amyloidosis Caused by Transthyretin (PHASE3)
- Doxycycline and TUDCA in Patients With Transthyretin Amyloid Cardiomyopathy (PHASE1, PHASE2)
- Safety, Efficacy and Pharmacokinetics of Doxycycline Plus Tauroursodeoxycholic Acid in Transthyretin Amyloidosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: